Course Summary

Lumateperone is a second-generation antipsychotic approved for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder, either as monotherapy or with lithium or valproate. It has a distinct mechanism of action, combining serotonin 5-HT₂A receptor antagonism, dopamine D₂ receptor modulation, and serotonin reuptake inhibition. This multimodal activity contributes to both antipsychotic and antidepressant effects. Compared to other atypical antipsychotics, lumateperone has a lower risk of metabolic side effects and extrapyramidal symptoms (EPS), making it a favorable option for patients with metabolic vulnerabilities. Unlike lurasidone, it does not require food for absorption, which may improve adherence.

Course Format

Homestudy

Course Syllabus

• Introduction
• Pharmacological Overview
• Therapeutic Applications in Psychiatry
• Dosing, Safety, and Use in Special Populations
  • Contraindications and Adverse Effects
  • Special Population Considerations
  • Toxicity and Monitoring
• Clinical Pearls: Lumaterperone
  • Fixed-Dose, No Titration Required
  • Low Risk of Extrapyramidal Symptoms (EPS)
  • Favorable Metabolic Profile
  • CYP3A4 Metabolism: Know the Interactions
  • Early Onset of Symptom Relief
• RX JOURNAL CLUB: Lumateperone in Clinical Context
  • Introduction
  • Study Objective
  • Methods
  • Efficacy Outcomes
  • Safety and Tolerability
  • Research Study Discussion
  • Current Treatment Guidelines
  • Study Limitations
  • Clinical Implications and Future Directions
  • Journal Club Conclusion
• Summary

Authors

Richard Daniels, PharmD, BCPS

Richard “Cole” Daniels earned his Doctor of Pharmacy(PharmD) from the Skaggs School of Pharmacy at the University of Montana in 2018. Throughout pharmacy school he completed a 3-year internship at Community Medical Center in Missoula, Montana in which he gained valuable experience in an acute care setting. Cole currently serves as a psychiatric clinical staff pharmacist at the Montana State Hospital. He has over 11 years of pharmacy experience having worked in several settings including retail, acute care, and inpatient psychiatric care. Cole has a diverse set of interests. However, acute care medicine, infectious disease, pain management, and asthma/COPD are a primary focus of his at the Montana State Hospital. He obtained board certification as a certified pharmacotherapy specialist in the Spring of 2022.

Elisabeth Gordon, BScPharm, RPh

Elisabeth Gordon earned her BSc(Pharm) from the University of British Columbia in 2004. After graduation, she worked in community retail pharmacies on Vancouver Island, before returning to her rural hometown of Salmon Arm. In 2016 and 2017, Elisabeth trained with Pallium Canada and Victoria Hospice to enhance her knowledge of end-of-life-care and palliative services. She is a volunteer medical supervisor for T1DOutreach, a peer support platform for adults living with type 1 diabetes, and a member of a Canadian peer support group for adults living with Birdshot Uveitis. Elisabeth enjoys working in a small, fast-paced rural pharmacy where she brings compassion and empathy to her everyday practice.